Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02695173 · ClinicalTrials.gov registry record
Complications of UTI in Patients on Dapagliflozin
A clinical trial of Severe Complications of Urinary Tract Infections, sponsored by AstraZeneca.
- Completed
- Registry status
- 683,380
- Enrollment target
- 3
- Study locations
NCT02695173: Completed study of Severe Complications of Urinary Tract Infections, sponsored by AstraZeneca.
NCT02695173 is a study of Severe Complications of Urinary Tract Infections that has completed, run by AstraZeneca. The registered enrollment target is 683,380 participants. The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02695173, a study of Severe Complications of Urinary Tract Infections, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 683,380 participants
- Enrollment target
- 3
- Study locations
Study Summary
The objective of this study is to compare, by insulin use at the index date, the sex-specific incidence of hospitalization or emergency department (ED) visit for severe complications of urinary tract infections (UTI), defined as pyelonephritis and urosepsis, among patients with type 2 diabetes mellitus (T2DM) who are new users of dapagliflozin with those who are new users of antidiabetic drugs (ADs) in classes other than sodium-glucose cotransporter 2 (SGLT2) inhibitors, insulin monotherapy, metformin monotherapy, or sulfonylurea monotherapy.
Primary Outcome
Patients will be followed from their index date (date of first study drug prescription or dispensing) until they experience one of the following: an event under study, end of time at risk for index medication, death, addition of a non-dapagliflozin SGLT2 inhibitor, termination of health plan or transfer out of the GP practice, or end of the study period (up to six years)
Conditions Studied
Study Locations (3)
Delaware
- Research Site - Wilmington
District of Columbia
- Research Site - Washington D.C.
Other
- Research Site - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 683,380 participants |
| Start Date | 2017-01-01 |
| Est. Completion | 2020-11-30 |
What the finished NCT02695173 record still lists
NCT02695173 is an observational study that tracks outcomes without assigning an intervention. Its 683,380 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with Severe Complications of Urinary Tract Infections appearing as the primary indexed condition, and to 0 interventions.
NCT02695173 reports a single indexed study location in Delaware, District of Columbia, Other.
Frequently Asked Questions
What is clinical trial NCT02695173 about?
NCT02695173 is a clinical study titled "Complications of UTI in Patients on Dapagliflozin". The objective of this study is to compare, by insulin use at the index date, the sex-specific incidence of hospitalization or emergency department (ED) visit for severe complications of urinary tract infections (UTI), defined as pyelonephritis and urosepsis, among patients with type 2 diabetes melli...
What is the current status of trial NCT02695173?
This trial is currently completed. The enrollment target is 683,380 participants. The study started on 2017-01-01. Estimated completion is 2020-11-30.
What conditions does trial NCT02695173 study?
This clinical trial studies the following conditions: Severe Complications of Urinary Tract Infections.
Who is sponsoring clinical trial NCT02695173?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02695173 being conducted?
This trial has 3 study locations across Delaware, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05065060 · 500,000 participants
Parkinson Progression Marker Initiative Online (PPMI Online)
- NCT06017687 · 500,000 participants · NA
Data Collection and Evaluation of OptiBP Under Investigational Use
- NCT06342375 · 425,000 participants · NA
Enrollment Barriers, Procedural Denials, and Loss of Medicaid Coverage
- NCT01073475 · 950,000 participants
Maternal Newborn Health Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI